Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Lenvatinib or anti-VEGF in combination with anti–PD-1 differentially augments antitumor activity in melanoma
Thuy T. Tran, Jasmine Caulfield, Lin Zhang, David Schoenfeld, Dijana Djureinovic, Veronica L. Chiang, Victor Oria, Sarah A. Weiss, Kelly Olino, Lucia B. Jilaveanu, Harriet M. Kluger
Thuy T. Tran, Jasmine Caulfield, Lin Zhang, David Schoenfeld, Dijana Djureinovic, Veronica L. Chiang, Victor Oria, Sarah A. Weiss, Kelly Olino, Lucia B. Jilaveanu, Harriet M. Kluger
View: Text | PDF
Research Article Oncology

Lenvatinib or anti-VEGF in combination with anti–PD-1 differentially augments antitumor activity in melanoma

  • Text
  • PDF
Abstract

Targeting tumor-associated blood vessels to increase immune infiltration may enhance treatment effectiveness, yet limited data exist regarding anti-angiogenesis effects on the tumor microenvironment (TME). We hypothesized that dual targeting of angiogenesis with immune checkpoints would improve both intracranial and extracranial disease. We used subcutaneous and left ventricle melanoma models to evaluate anti–PD-1/anti-VEGF and anti–PD-1/lenvatinib (pan-VEGFR inhibitor) combinations. Cytokine/chemokine profiling and flow cytometry were performed to assess signaling and immune-infiltrating populations. An in vitro blood-brain barrier (BBB) model was utilized to study intracranial treatment effects on endothelial integrity and leukocyte transmigration. Anti–PD-1 with either anti-VEGF or lenvatinib improved survival and decreased tumor growth in systemic melanoma murine models; treatment increased Th1 cytokine/chemokine signaling. Lenvatinib decreased tumor-associated macrophages but increased plasmacytoid DCs early in treatment; this effect was not evident with anti-VEGF. Both lenvatinib and anti-VEGF resulted in decreased intratumoral blood vessels. Although anti-VEGF promoted endothelial stabilization in an in vitro BBB model, while lenvatinib did not, both regimens enabled leukocyte transmigration. The combined targeting of PD-1 and VEGF or its receptors promotes enhanced melanoma antitumor activity, yet their effects on the TME are quite different. These studies provide insights into dual anti–PD-1 and anti-angiogenesis combinations.

Authors

Thuy T. Tran, Jasmine Caulfield, Lin Zhang, David Schoenfeld, Dijana Djureinovic, Veronica L. Chiang, Victor Oria, Sarah A. Weiss, Kelly Olino, Lucia B. Jilaveanu, Harriet M. Kluger

×

Figure 4

Combined antivascular-directed therapies and anti–PD-1 enhance antitumor inflammatory cytokines and chemokines.

Options: View larger image (or click on image) Download as PowerPoint
Combined antivascular-directed therapies and anti–PD-1 enhance antitumor...
The change in cytokine levels after 2 i.p. treatments and/or a week of daily lenvatinib in the YUMMER1.7 LV melanoma model demonstrated enhanced macrophage activation and Th1 responses, particularly with anti–PD-1/lenvatinib. The T cell-stimulating cytokines IL-2, eotaxin, and IL-17 were elevated with anti-VEGF treatment. Cytokines associated with macrophage activation (G-CSF, MIP-1a, MIP-1B, M-CSF, and MIP-2) and T cell stimulation (IL-1a, MIG, IL-7, IL-15, IFN-γ, and IL-12p40), particularly Th1 cells (IL-2, TNF-α, IFN-γ, GM-CSF, IL-12p40, and IL-12p70) were increased with anti–PD-1/lenvatinib treatment even more so than with anti–PD-1/anti-VEGF treatment.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts